Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?

Stem Cells

Volumn 28, Issue 9, 2010, Pages 1686-1702

  Tang, Catherine ^a   Russell, Pamela J ^a   Martiniello Wilks, Rosetta ^b,c   Rasko, John E J ^b,c   Khatri, Aparajita ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cancer; Gene therapy; Magnetic nanoparticles; Mesenchymal stem cells; Nanotechnology; SPION; Stem cell tracking and imaging

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BETA INTERFERON; CHEMOKINE RECEPTOR CXCR4; CYTOSINE DEAMINASE; DAUNORUBICIN; DENDRIMER; DOXORUBICIN; DRUG CARRIER; FERRITIN; FERUCARBOTRAN; FLUOROCARBON; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FRACTALKINE; GADOLINIUM; GANCICLOVIR; INTERLEUKIN 2; MANGANESE; NANOPARTICLE; POLYLYSINE; PROTAMINE SULFATE; RADIOISOTOPE; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; THYMIDINE KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VIRUS VECTOR; CONTRAST MEDIUM; DEXTRAN; MAGNETITE; MAGNETITE NANOPARTICLE;

ACCURACY; CANCER DIAGNOSIS; CANCER GENE THERAPY; DIAGNOSTIC IMAGING; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; IMAGE ENHANCEMENT; IMMUNOGENICITY; MESENCHYMAL STEM CELL; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SAFETY; TRANSGENE; ANIMAL; DIAGNOSTIC USE; GENE THERAPY; GENE TRANSFER; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR IMAGING; NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; CONTRAST MEDIA; FERROSOFERRIC OXIDE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MAGNETIC RESONANCE IMAGING; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR IMAGING; NANOPARTICLES; NEOPLASMS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; DEXTRANS; GENETIC THERAPY; MAGNETITE NANOPARTICLES;

EQUIDAE;

EID: 77958113961     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.473     Document Type: Review

References (236)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150. (Pubitemid 46655601)
2. WHO. Available at http://www.who.int/mediacentre/factsheets/fs297/en/ index.html. Accessed July 2008.
3. Weissleder R. Molecular imaging in cancer. Science 2006;312:1168-1171.
4. Nakashima J, Tanimoto A, Kikuchi E et al. Clinical implications of tumor size and local extent of primary prostatic lesions in prostate cancer patients with metastases: Value of endorectal magnetic resonance imaging in patients with metastases. Urology 2007;70:86-90.
5. Majhen D Ambriovic-Ristov A. Adenoviral vectors-How to use them in cancer gene therapy? Virus Res 2006;119:121-133.
6. Chamberlain G, Fox J, Ashton B et al. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25:2739-2749.
7. Sykova E, Jendelova P. Migration, fate and in vivo imaging of adult stem cells in the CNS. Cell Death Differ 2007;14:1336-1342. (Pubitemid 46965263)
8. Kim D, Chun BG, Kim YK et al. In vivo tracking of human mesenchymal stem cells in experimental stroke. Cell Transplant 2008;16:1007-1012.
9. Aboody KS, Brown A, Rainov NG et al. Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000;97:12846-12851.
10. Tabatabai G, Bahr O, Mohle R et al. Lessons from the bone marrow: How malignant glioma cells attract adult haematopoietic progenitor cells. Brain 2005;128:2200-2211.
11. Corsten MF, Shah K. Therapeutic stem-cells for cancer treatment: Hopes and hurdles in tactical warfare. Lancet Oncol 2008;9:376-384.
12. Hoehn M, Kustermann E, Blunk J et al. Monitoring of implanted stem cell migration in vivo: A highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. Proc Natl Acad Sci USA 2002;99:16267-16272.
13. Ittrich H, Lange C, Togel F et al. In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: Detection and monitoring at 3T. J Magn Reson Imaging 2007;25:1179-1191.
14. Fidler IJ. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-458.
15. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659.
16. Li H, Fan X, Houghton J. Tumor microenvironment: The role of the tumor stroma in cancer. J Cell Biochem 2007;101:805-815. (Pubitemid 47040863)
17. Chantrain CF, Henriet P, Jodele S et al. Mechanisms of pericyte recruitment in tumour angiogenesis: A new role for metalloproteinases. Eur J Cancer 2006;42:310-318.
18. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth - Bystanders turning into key players. Curr Opin Genet Dev 2009;19:67-73.
19. Oh MC, Lim DA. Novel treatment strategies for malignant gliomas using neural stem cells. Neurotherapeutics 2009;6:458-464.
20. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: Underlying mechanisms and translation to the clinic. Lancet Neurol 2009;8:491-500.
21. Khanna A, Shin S, Rao MS. Stem cells for the treatment of neurological disorders. CNS Neurol Disord Drug Target 2008;7:98-109.
22. Konopleva M, Tabe Y, Zeng Z et al. Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches. Drug Resist Update 2009;12:103-113.
23. Markowicz S. Harnessing stem cells and dendritic cells for novel therapies. Acta Polym Pharm 2008;65:625-632.
24. Biffi A, Cesani M. Human hematopoietic stem cells in gene therapy: Pre-clinical and clinical issues. Curr Gene Ther 2008;8:135-146.
25. Altaner C. Glioblastoma and stem cells. Neoplasma 2008;55:369-374.
26. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-49.
27. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
28. Sykova E, Jendelova P. Magnetic resonance tracking of implanted adult and embryonic stem cells in injured brain and spinal cord. Ann N Y Acad Sci 2005;1049:146-160.
29. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol 1976;47:327-359.
30. Gimble J, Guilak F. Adipose-derived adult stem cells: Isolation, characterization, and differentiation potential. Cytotherapy 2003;5:362-369.
31. Vaananen HK. Mesenchymal stem cells. Ann Med 2005;37:469-479.
32. Owen M, Friedenstein AJ. Stromal stem cells: Marrow-derived osteogenic precursors. Ciba Found Symp 1988;136:42-60.
33. Conget PA, Minguell JJ. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 1999;181:67-73.
34. Colter DC, Class R, DiGirolamo CM et al. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci USA 2000;97:3213-3218.
35. Pittenger MF. Mesenchymal stem cells from adult bone marrow. Methods Mol Biol 2008;449:27-44.
36. Pittenger MF, Mosca JD, McIntosh KR. Human mesenchymal stem cells: Progenitor cells for cartilage, bone, fat and stroma. Curr Top Microbiol Immunol 2000;251:3-11.
37. Chan J, O'Donoghue K, de la Fuente J et al. Human fetal mesenchymal stem cells as vehicles for gene delivery. Stem Cells 2005;23:93-102.
38. Lee K, Majumdar MK, Buyaner D et al. Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther 2001;3:857-866.
39. Ryan JM, Barry FP, Murphy JM et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005;2:8-18.
40. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890-896.
41. Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-3318.
42. Nakamura K, Ito Y, Kawano Y et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11:1155-1164.
43. Ishii G, Sangai T, Oda T et al. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun 2003;309:232-240.
44. Direkze NC, Hodivala-Dilke K, Jeffery R et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004;64:8492-8495.
45. Hurwitz DR, Kirchgesser M, Merrill W et al. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum Gene Ther 1997;8:137-156.
46. Krebsbach PH, Zhang K, Malik AK et al. Bone marrow stromal cells as a genetic platform for systemic delivery of therapeutic proteins in vivo: Human factor IX model. J Gene Med 2003;5:11-17. (Pubitemid 40310363)
47. Brooke G, Cook M, Blair C et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol 2007;18:846-858.
48. Hall B, Dembinski J, Sasser AK et al. Mesenchymal stem cells in cancer: Tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol 2007;86:8-16.
49. Wu X, Hu J, Zhou L et al. In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging. Laboratory investigation. J Neurosurg 2008;108:320-329.
50. Studeny M, Marini FC, Champlin RE et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002;62:3603-3608.
51. Stoff-Khalili MA, Rivera AA, Mathis JM et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007;105:157-167.
52. Mohr A, Lyons M, Deedigan L et al. Mesenchymal Stem Cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008;12:2628-2643.
53. Dwyer RM, Potter-Beirne SM, Harrington KA et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007;13:5020-5027.
54. Komarova S, Kawakami Y, Stoff-Khalili MA et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006;5:755-766.
55. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-1603. (Pubitemid 39534883)
56. Menon LG, Picinich S, Koneru R et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 2007;25:520-528.
57. Forte G, Minieri M, Cossa P et al. Hepatocyte growth factor effects on mesenchymal stem cells: Proliferation, migration, and differentiation. Stem Cells 2006;24:23-33.
58. Schichor C, Birnbaum T, Etminan N et al. Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol 2006;199:301-310.
59. Son BR, Marquez-Curtis LA, Kucia M et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006;24:1254-1264.
60. Spaeth E, Klopp A, Dembinski J et al. Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008;15:730-738.
61. Birnbaum T, Roider J, Schankin CJ et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 2007;83:241-247.
62. Li SC et al. Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies. Curr Stem Cell Res Ther 2010; Epub ahead of print.
63. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008;15:739-752.
64. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4:346-358.
65. Chirmule N, Propert K, Magosin S et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999;6:1574-1583. (Pubitemid 29465516)
66. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008;132:1-14.
67. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol 2007;36:71-80.
68. Yang TC, Millar JB, Grinshtein N et al. T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev Vaccines 2007;6:347-356.
69. Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007;7:189-204.
70. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003;75:389-397.
71. Le Blanc K, Pittenger M. Mesenchymal stem cells: Progress toward promise. Cytotherapy 2005;7:36-45.
72. Pereboeva L, Komarova S, Mikheeva G et al. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 2003;21:389-404.
73. Kurozumi K, Nakamura K, Tamiya T et al. BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. Mol Ther 2004;9:189-197.
74. Xin H, Kanehira M, Mizuguchi H et al. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007;25:1618-1626. (Pubitemid 47121838)
75. Hakkarainen T, Sarkioja M, Lehenkari P et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther 2007;18:627-641.
76. Kucerova L, Altanerova V, Matuskova M et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007;67:6304-6313.
77. Kucerova L, Matuskova M, Pastorakova A et al. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 2008;10:1071-1082.
78. Kawabata K, Sakurai F, Koizumi N et al. Adenovirus vector-mediated gene transfer into stem cells. Mol Pharm 2006;3:95-103. (Pubitemid 43672245)
79. Conget PA, Minguell JJ. Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol 2000;28:382-390.
80. Mizuguchi H, Sasaki T, Kawabata K et al. Fiber-modified adenovirus vectors mediate efficient gene transfer into undifferentiated and adipogenic-differentiated human mesenchymal stem cells. Biochem Biophys Res Commun 2005;332:1101-1106.
81. Djouad F, Bony C, Apparailly F et al. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006;82:1060-1066.
82. Sasportas LS, Kasmieh R, Wakimoto H et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009;106:4822-4827.
83. Miletic H, Fischer Y, Litwak S et al. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther 2007;15:1373-1381.
84. Bieback K, Kern S, Kocaomer A et al. Comparing mesenchymal stromal cells from different human tissues: Bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng 2008;18:S71-S76.
85. Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24:1294-1301.
86. Jaiswal S, Jamieson CH, Pang WW et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009;138:271-285.
87. Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009;138:286-299.
88. Wang H, Chen X. Imaging mesenchymal stem cell migration and the implications for stem cell-based cancer therapies. Future Oncol 2008;4:623-628.
89. Barrett T, Brechbiel M, Bernardo M et al. MRI of tumor angiogenesis. J Magn Reson Imaging 2007;26:235-249.
90. Kidd S, Spaeth E, Dembinski JL et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009;27:2614-2623.
91. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-589.
92. Fass L. Imaging and cancer: A review. Mol Oncol 2008;2:115-152.
93. Schnall M, Rosen M. Primer on imaging technologies for cancer. J Clin Oncol 2006;24:3225-3233.
94. Iyer M, Sato M, Johnson M et al. Applications of molecular imaging in cancer gene therapy. Curr Gene Ther 2005;5:607-618.
95. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA 2005;293:855-862.
96. Love Z, Wang F, Dennis J et al. Imaging of mesenchymal stem cell transplant by bioluminescence and PET. J Nucl Med 2007;48:2011-2020.
97. MacLaren DC, Toyokuni T, Cherry SR et al. PET imaging of transgene expression. Biol Psychiatry 2000;48:337-348.
98. Kraitchman DL, Heldman AW, Atalar E et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 2003;107:2290-2293.
99. Long CM, Bulte JW. In vivo tracking of cellular therapeutics using magnetic resonance imaging. Expert Opin Biol Ther 2009;9:293-306.
100. Modo M. Noninvasive imaging of transplanted cells. Curr Opin Organ Transplant 2008;13:654-658.
101. Budde MD, Frank JA. Magnetic tagging of therapeutic cells for MRI. J Nucl Med 2009;50:171-174.
102. Kraitchman DL, Bulte JW. Imaging of stem cells using MRI. Basic Res Cardiol 2008;103:105-113.
103. Kalish H, Arbab AS, Miller BR et al. Combination of transfection agents and magnetic resonance contrast agents for cellular imaging: Relationship between relaxivities, electrostatic forces, and chemical composition. Magn Reson Med 2003;50:275-282.
104. Dodd CH, Hsu HC, Chu WJ et al. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide- derived superparamagnetic nanoparticles. J Immunol Methods 2001;256:89-105.
105. Muja N, Bulte J. Magnetic resonance imaging of cells in experimental models. Prog Nucl Reson Spectrosc 2009;55:61-77.
106. Waters EA, Wickline SA. Contrast agents for MRI. Basic Res Cardiol 2008;103:114-121.
107. Fukumori Y, Ichikawa H. Nanoparticles for cancer therapy and diagnosis. Adv Powder Technol 2006;17:1-28.
108. Iyer AK, Khaled G, Fang J et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11:812-818. (Pubitemid 44280021)
109. Cho K, Wang X, Nie S et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310-1316.
110. Tang M. Promise of Novel Magnetic Nanoparticles in Enhancement of Adenoviral Gene Delivery. Sydney: Faculty of Medicine, University of New South Wales, 2007.
111. Jones CF, Grainger DW. In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev 2009;61:438-456.
112. Lee HM, Shin DM, Song HM et al. Nanoparticles up-regulate tumor necrosis factor-alpha and CXCL8 via reactive oxygen species and mitogen-activated protein kinase activation. Toxicol Appl Pharmacol 2009;238:160-169.
113. Alexis F, Rhee JW, Richie JP et al. New frontiers in nanotechnology for cancer treatment. Urol Oncol 2008;26:74-85.
114. Cheon J, Lee JH. Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology. Acc Chem Res 2008.
115. Cao YC. Nanomaterials for biomedical applications. Nanomedicine 2008;3:467-469.
116. Lee JH, Huh YM, Jun YW et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007;13:95-99.
117. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. Eur Radiol 2001;11:2319-2331.
118. Shubayev VI, Pisanic TR, II, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 2009;61:467-477.
119. Gao J, Gu H, Xu B. Multifunctional magnetic nanoparticles: Design, synthesis, and biomedical applications. Acc Chem Res 2009;42:1097-1107.
120. Seneterre E, Taourel P, Bouvier Y et al. Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996;200:785-792.
121. Mack MG, Balzer JO, Straub R et al. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 2002;222:239-244. (Pubitemid 34031494)
122. Harisinghani MG, Barentsz JO, Hahn PF et al. MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer. Acad Radiol 2002;9(suppl 2):S312-S313.
123. Feldman AS, McDougal WS, Harisinghani MG. The potential of nanoparticle-enhanced imaging. Urol Oncol 2008;26:65-73.
124. Sadek H, Latif S, Collins R et al. Use of ferumoxides for stem cell labeling. Regen Med 2008;3:807-816.
125. Neuberger T, Schöpf B, Hofmann H et al. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater 2005;293:483-496.
126. Gupta AK, Gupta M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 2005;26:1565-1573.
127. Duguet E, Vasseur S, Mornet S et al. Magnetic nanoparticles and their applications in medicine. Nanomedicine 2006;1:157-168.
128. Gupta AK, Naregalkar RR, Vaidya VD et al. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine 2007;2:23-39.
129. Gurzau ES, Neagu C, Gurzau AE. Essential metals-case study on iron. Ecotoxicol Environ Saf 2003;56:190-200.
130. Thorek DL, Chen AK, Czupryna J et al. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 2006;34:23-38.
131. Arbab AS, Yocum GT, Rad AM et al. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed 2005;18:553-559. (Pubitemid 43013896)
132. Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: Double-blind, randomised controlled trial. Lancet 2006;367:113-121.
133. Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-1221. (Pubitemid 44427445)
134. Stuckey DJ, Carr CA, Martin-Rendon E et al. Iron particles for noninvasive monitoring of bone marrow stromal cell engraftment into, and isolation of viable engrafted donor cells from, the heart. Stem Cells 2006;24:1968-1975.
135. Anderson SA, Glod J, Arbab AS et al. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 2005;105:420-425.
136. Carr CA, Stuckey DJ, Tatton L et al. Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: An in vivo cine-MRI study. Am J Physiol Heart Circ Physiol 2008;295:H533-H542.
137. Kraitchman DL, Tatsumi M, Gilson WD et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005;112:1451-1461.
138. Jendelova P, Herynek V, Urdzikova L et al. Magnetic resonance tracking of transplanted bone marrow and embryonic stem cells labeled by iron oxide nanoparticles in rat brain and spinal cord. J Neurosci Res 2004;76:232-243.
139. Sykova E, Jendelova P. In vivo tracking of stem cells in brain and spinal cord injury. Prog Brain Res 2007;161:367-383.
140. Moore XL, Lu J, Sun L et al. Endothelial progenitor cells' "homing" specificity to brain tumors. Gene Ther 2004;11:811-818.
141. Huszthy PC, Giroglou T, Tsinkalovsky O et al. Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. Plos One 2009;4:e6314.
142. Zhao D, Najbauer J, Garcia E et al. Neural stem cell tropism to glioma: Critical role of tumor hypoxia. Mol Cancer Res 2008;6:1819-1829.
143. Yip S, Aboody KS, Burns M et al. Neural stem cell biology may be well suited for improving brain tumor therapies. Cancer J 2003;9:189-204.
144. Delcroix GJ, Jacquart M, Lemaire L et al. Mesenchymal and neural stem cells labeled with HEDP-coated SPIO nanoparticles: In vitro characterization and migration potential in rat brain. Brain Res 2009;1255:18-31.
145. Zhu W, Li X, Tang Z et al. Superparamagnetic iron oxide labeling of neural stem cells and 4.7T MRI tracking in vivo and in vitro. J Huazhong Univ Sci Technol Med Sci 2007;27:107-110.
146. Shah K. Imaging neural stem cell fate in mouse model of glioma. Curr Protoc Stem Cell Biol 2009;Chapter 5:Unit 5A 1.
147. Waerzeggers Y, Klein M, Miletic H et al. Multimodal imaging of neural progenitor cell fate in rodents. Mol Imaging 2008;7:77-91.
148. Brekke C, Williams SC, Price J et al. Cellular multiparametric MRI of neural stem cell therapy in a rat glioma model. Neuroimage 2007;37:769-782.
149. Song M, Kim Y, Kim Y et al. MRI tracking of intravenously transplanted human neural stem cells in rat focal ischemia model. Neurosci Res 2009;64:235-239.
150. Ruiz-Cabello J, Walczak P, Kedziorek DA et al. In vivo "hot spot" MR imaging of neural stem cells using fluorinated nanoparticles. Magn Reson Med 2008;60:1506-1511.
151. Zhang Z, Jiang Q, Jiang F et al. In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. Neuroimage 2004;23:281-287.
152. Pereboeva L, Curiel DT. Cellular vehicles for cancer gene therapy: Current status and future potential. Biodrugs 2004;18:361-385.
153. Amado LC, Saliaris AP, Schuleri KH et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 2005;102:11474-11479.
154. Walczak P, Kedziorek DA, Gilad AA et al. Applicability and limitations of MR tracking of neural stem cells with asymmetric cell division and rapid turnover: The case of the shiverer dysmyelinated mouse brain. Magn Reson Med 2007;58:261-269. (Pubitemid 47267643)
155. Pawelczyk E, Arbab AS, Chaudhry A et al. In vitro model of bromodeoxyuridine or iron oxide nanoparticle uptake by activated macrophages from labeled stem cells: Implications for cellular therapy. Stem Cells 2008;26:1366-1375.
156. Frangioni JV, Hajjar RJ. In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation 2004;110:3378-3383.
157. Matuszewski L, Persigehl T, Wall A et al. Cell tagging with clinically approved iron oxides: Feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology 2005;235:155-161.
158. Lewin M, Carlesso N, Tung CH et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000;18:410-414.
159. Bulte JW, Douglas T, Witwer B et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 2001;19:1141-1147.
160. Arbab AS, Bashaw LA, Miller BR et al. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: Methods and techniques. Transplantation 2003;76:1123-1130.
161. Arbab AS, Yocum GT, Kalish H et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 2004;104:1217-1223.
162. Frank JA, Miller BR, Arbab AS et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology 2003;228:480-7.
163. Walczak P, Kedziorek DA, Gilad AA et al. Instant MR labeling of stem cells using magnetoelectroporation. Magn Reson Med 2005;54:769-774.
164. Bulte JW, Arbab AS, Douglas T et al. Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Methods Enzymol 2004;386:275-299.
165. Daniels TR, Delgado T, Rodriguez JA et al. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006;121:144-158.
166. Gatter KC, Brown G, Trowbridge IS et al. Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J Clin Pathol 1983;36:539-545.
167. Daniels TR, Delgado T, Helguera G et al. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006;121:159-176.
168. Arbab AS, Yocum GT, Wilson LB et al. Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability. Mol Imaging 2004;3:24-32.
169. Janic B, Rad AM, Jordan EK et al. Optimization and validation of FePro cell labeling method. Plos One 2009;4:e5873.
170. Kostura L, Kraitchman DL, Mackay AM et al. Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. NMR Biomed 2004;17:513-517.
171. Daldrup-Link HE, Meier R, Rudelius M et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol 2005;15:4-13.
172. Himmelreich U, Hoehn M. Stem cell labeling for magnetic resonance imaging. Minim Invasive Ther Allied Technol 2008;17:132-142. (Pubitemid 351942706)
173. Kustermann E, Himmelreich U, Kandal K et al. Efficient stem cell labeling for MRI studies. Contrast Media Mol Imaging 2008;3:27-37. (Pubitemid 351493976)
174. Montet-Abou K, Montet X, Weissleder R et al. Cell internalization of magnetic nanoparticles using transfection agents. Mol Imaging 2007;6:1-9.
175. Anderson CJ, Bulte JW, Chen K et al. Design of targeted cardiovascular molecular imaging probes. J Nucl Med 2010;51(Suppl 1):3S-17S. Epub 2010 Apr 15.
176. Song M, Moon WK, Kim Y et al. Labeling efficacy of superparamagnetic iron oxide nanoparticles to human neural stem cells: Comparison of ferumoxides, monocrystalline iron oxide, cross-linked iron oxide (CLIO)-NH2 and tat-CLIO. Korean J Radiol 2007;8:365-371.
177. Bulte JW, Ben-Hur T, Miller BR et al. MR microscopy of magnetically labeled neurospheres transplanted into the Lewis EAE rat brain. Magn Reson Med 2003;50:201-205.
178. Gamarra LF, Pavon LF, Marti LC et al. In vitro study of CD133 human stem cells labeled with superparamagnetic iron oxide nanoparticles. Nanomedicine 2008;4:330-339.
179. Bulte JW, Douglas T, Witwer B et al. Monitoring stem cell therapy in vivo using magnetodendrimers as a new class of cellular MR contrast agents. Acad Radiol 2002;9(suppl 2):S332-S335.
180. Schafer R, Kehlbach R, Muller M et al. Labeling of human mesenchymal stromal cells with superparamagnetic iron oxide leads to a decrease in migration capacity and colony formation ability. Cytotherapy 2009;11:68-78.
181. Schafer R, Kehlbach R, Wiskirchen J et al. Transferrin receptor upregulation: In vitro labeling of rat mesenchymal stem cells with superparamagnetic iron oxide. Radiology 2007;244:514-523.
182. Gilad AA, Walczak P, McMahon MT et al. MR tracking of transplanted cells with "positive contrast" using manganese oxide nanoparticles. Magn Reson Med 2008;60:1-7.
183. Modo M, Mellodew K, Cash D et al. Mapping transplanted stem cell migration after a stroke: A serial, in vivo magnetic resonance imaging study. Neuroimage 2004;21:311-317.
184. Anderson SA, Lee KK, Frank JA. Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. Invest Radiol 2006;41:332-338.
185. Brekke C, Morgan SC, Lowe AS et al. The in vitro effects of a bimodal contrast agent on cellular functions and relaxometry. NMR Biomed 2007;20:77-89.
186. Ahrens ET, Feili-Hariri M, Xu H et al. Receptor-mediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn Reson Med 2003;49:1006-1013. (Pubitemid 36627278)
187. Partlow KC, Chen J, Brant JA et al. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J 2007;21:1647-1654.
188. Choi JS, Park JC, Nah H et al. A hybrid nanoparticle probe for dualmodality positron emission tomography and magnetic resonance imaging. Angew Chem Int Ed Engl 2008;47:6259-6262.
189. Foster-Gareau P, Heyn C, Alejski A et al. Imaging single mammalian cells with a 1.5 T clinical MRI scanner. Magn Reson Med 2003;49:968-971.
190. Heyn C, Ronald JA, Mackenzie LT et al. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 2006;55:23-29.
191. Srinivas M, Morel PA, Ernst LA et al. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn Reson Med 2007;58:725-734. (Pubitemid 47556877)
192. Gilad AA, Ziv K, McMahon MT et al. MRI reporter genes. J Nucl Med 2008;49:1905-1908.
193. Plank C, Schillinger U, Scherer F et al. The magnetofection method: Using
194. Scherer F, Anton M, Schillinger U et al. Magnetofection: Enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002;9:102-109.
195. Bhattarai SR, Kim SY, Jang KY et al. N-hexanoyl chitosan-stabilized magnetic nanoparticles: Enhancement of adenoviral-mediated gene expression both in vitro and in vivo. Nanomedicine 2008;4:146-154.
196. Pichler BJ, Wehrl HF, Judenhofer MS. Latest advances in molecular imaging instrumentation. J Nucl Med 2008;49(suppl 2):5S-23S.
197. Pichler BJ, Wehrl HF, Kolb A et al. Positron emission tomography/magnetic resonance imaging: The next generation of multimodality imaging? Semin Nucl Med 2008;38:199-208.
198. Dousset V, Ballarino L, Delalande C et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. AJNR Am J Neuroradiol 1999;20:223-227.
199. Judenhofer MS, Wehrl HF, Newport DF et al. Simultaneous PETMRI: A new approach for functional and morphological imaging. Nat Med 2008;14:459-465.
200. Catana C, Procissi D, Wu Y et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci USA 2008;105:3705-3710. (Pubitemid 351723462)
201. Pichler BJ, Judenhofer MS, Pfannenberg C. Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol 2008;109-132.
202. Lee Z, Dennis JE, Gerson SL. Imaging stem cell implant for cellular-based therapies. Exp Biol Med (Maywood) 2008;233:930-940.
203. Aisen P. Transferrin, the transferrin receptor, and the uptake of iron by cells. Met Ions Biol Syst 1998;35:585-631.
204. Aisen P. Ferritin receptors and the role of ferritin in iron transport. Target Diagn Ther 1991;4:339-354.
205. Ikuta K, Zak O, Aisen P. Recycling, degradation and sensitivity to the synergistic anion of transferrin in the receptor-independent route of iron uptake by human hepatoma (HuH-7) cells. Int J Biochem Cell Biol 2004;36:340-352.
206. Bulte JW, Zhang S, van Gelderen P et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: Magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci USA 1999;96:15256-15261.
207. Genove G, DeMarco U, Xu H et al. A new transgene reporter for in vivo magnetic resonance imaging. Nat Med 2005;11:450-454. (Pubitemid 40562338)
208. Zurkiya O, Chan AW, Hu X. MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter. Magn Reson Med 2008;59:1225-1231. (Pubitemid 351813249)
209. Alfke H, Stoppler H, Nocken F et al. In vitro MR imaging of regulated gene expression. Radiology 2003;228:488-492.
210. Ramadan SS, Heyn C, Mackenzie LT et al. Ex-vivo cellular MRI with b-SSFP: Quantitative benefits of 3T over 1.5 T. Magn Reson Mater Phys Biol Med 2008;21:251-259.
211. Heyn C, Ronald JA, Mackenzie LT et al. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 2006;55:23-29.
212. Hinds KA, Hill JM, Shapiro EM et al. Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells. Blood 2003;102:867-872.
213. Shapiro EM, Skrtic S, Sharer K et al. MRI detection of single particles for cellular imaging. Proc Natl Acad Sci USA 2004;101:10901-10906. (Pubitemid 38989558)
214. Kircher MF, Mahmood U, King RS et al. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003;63:8122-8125. (Pubitemid 37549457)
215. Josephson L, Kircher MF, Mahmood U et al. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem 2002;13:554-560. (Pubitemid 34527517)
216. Wang S, Jarrett BR, Kauzlarich SM et al. Core/shell quantum dots with high relaxivity and photoluminescence for multimodality imaging. J Am Chem Soc 2007;129:3848-3856. (Pubitemid 46595506)
217. Huber MM, Staubli AB, Kustedjo K et al. Fluorescently detectable magnetic resonance imaging agents. Bioconjug Chem 1998;9:242-249. (Pubitemid 28147142)
218. Zhang Z, Liang K, Bloch S et al. Monomolecular multimodal fluorescence-radioisotope imaging agents. Bioconjug Chem 2005;16:1232-1239.
219. Zielhuis SW, Seppenwoolde JH, Mateus VA et al. Lanthanide-loaded liposomes for multimodality imaging and therapy. Cancer Biother Radiopharm 2006;21:520-527.
220. Hill JM, Dick AJ, Raman VK et al. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation 2003;108:1009-1014.
221. de Vries IJ, Lesterhuis WJ, Barentsz JO et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23:1407-1413.
222. Park KS, Tae J, Choi B et al. Characterization, in vitro cytotoxicity assessment, and in vivo visualization of multimodal, RITC-labeled, silica-coated magnetic nanoparticles for labeling human cord blood-derived mesenchymal stem cells. Nanomedicine 2009.
223. Jackson J, Chapon C, Jones W et al. In vivo multimodal imaging of stem cell transplantation in a rodent model of Parkinson's disease. J Neurosci Methods 2009;183:141-148.
224. Chapon C, Jackson JS, Aboagye EO et al. An in vivo multimodal imaging study using MRI and PET of stem cell transplantation after myocardial infarction in rats. Mol Imaging Biol 2009;11:31-38.
225. Zinn KR, Chaudhuri TR, Szafran AA et al. Noninvasive bioluminescence imaging in small animals. ILAR J 2008;49:103-115.
226. Myhr G. MR guided cancer treatment system for an elevated therapeutic index - A macroscopic approach. Med Hypotheses 2008;70:665-670. (Pubitemid 351179915)
227. Cao F, Drukker M, Lin S et al. Molecular imaging of embryonic stem cell misbehavior and suicide gene ablation. Cloning Stem Cells 2007;9:107-117. (Pubitemid 46642075)
228. Cao F, Lin S, Xie X et al. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation 2006;113:1005-1014.
229. De Palma M, Venneri MA, Roca C et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003;9:789-795. (Pubitemid 36749231)
230. Kang JH, Lee DS, Paeng JC et al. Development of a sodium/iodide symporter (NIS)-transgenic mouse for imaging of cardiomyocyte-specific reporter gene expression. J Nucl Med 2005;46:479-483.
231. Choi SC, Shim WJ, Lim DS. Specific monitoring of cardiomyogenic and endothelial differentiation by dual promoter-driven reporter systems in bone marrow mesenchymal stem cells. Biotechnol Lett 2008;30:835-843.
232. Kumar S, Mahendra G, Ponnazhagan S. Determination of osteoprogenitor- specific promoter activity in mouse mesenchymal stem cells by recombinant adeno-associated virus transduction. Biochim Biophys Acta 2005;1731:95-103.
233. Lee OK, Kuo TK, Chen WM et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004;103:1669-1675. (Pubitemid 38268958)
234. Kim SM, Lim JY, Park SI et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68:9614-9623.
235. Klopp AH, Spaeth EL, Dembinski JL et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007;67:11687-11695.
236. Zielske SP, Livant DL, Lawrence TS. Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys 2009;75:843-853. Epub 2008 Oct 11.